PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
10 nov. 2021 07h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute
08 nov. 2021 08h30 HE
|
PDS Biotechnology Corporation
Advances Next Phase of Versamune® Oncology Pipeline FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company...
PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer
06 oct. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer
04 oct. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotechnology to Present at the Benzinga Healthcare Conference
27 sept. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”, Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer...
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer
20 sept. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
15 sept. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
13 sept. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
09 sept. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 08h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...